|
業務類別
|
Biotechnology |
|
業務概覽
|
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases. |
| 公司地址
| 92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY |
| 電話號碼
| +44 1235438600 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.immunocore.com |
| 員工數量
| 524 |
| Mr. John Goll |
Senior Vice President, Finance and Chief Accounting Officer |
-- |
25/02/2026 |
| Dr. Bahija Jallal, PhD |
Chief Executive Officer and Director |
美元 760.00K |
25/02/2026 |
| Mr. Travis Coy |
Executive Vice President, Chief Financial Officer and Head of Corporate Development |
-- |
25/02/2026 |
| Ms. Tina St. Leger |
Chief Human Resources Officer |
美元 361.69K |
28/11/2025 |
|
|
| Mr. Robert J. Perez |
Independent Director |
04/04/2025 |
| Ms. Kristine Peterson |
Independent Director |
25/02/2026 |
| Dr. Bahija Jallal, PhD |
Chief Executive Officer and Director |
25/02/2026 |
| Professor Sir John Bell |
Chairman of the Board |
25/02/2026 |
| Mr. Roy Steven Herbst, M.D.,PhD |
Independent Director |
25/02/2026 |
| Mr. Siddharth Kaul |
Independent Director |
25/02/2026 |
| Professor Sir Peter Ratcliffe |
Independent Director |
25/02/2026 |
| Dr. William Pao, M.D.,PhD |
Director |
25/02/2026 |
|
|
|
|
